MIA LEVY was named director of Cancer Health Information and Strategy at Vanderbilt-Ingram Cancer Center. Levy is the Ingram Assistant Professor of Cancer Research and director of Cancer Clinical Informatics at the center.
ROBERT HAUSER was named vice president of clinical analytics at Cancer Treatment Centers of America Medicine & Science.
FDA approved Opdivo (nivolumab) injection for the treatment of patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy.
JENNIFER NAM CHOI was named chief of the Division of OncoDermatology at Northwestern Memorial Hospital and associate professor in the Department of Dermatology at Northwestern University Feinberg School of Medicine. Choi will also join the melanoma team at Northwestern Medicine.
NCI awarded about 635 R01s in 2015, up from 629 in 2014, said NCI Acting Director Doug Lowy at a recent joint meeting of the National Cancer Advisory Board and the NCI Board of Scientific Advisors.
On Nov. 17, Richard Pazdur, director at the FDA Office of Hematology and Oncology Products, spoke about the role that has been thrust upon him: that of a “regulator/advocate.”
Caris Life Sciences and Syapse will collaborate to collect and combine molecular and genomic information with clinical treatment and outcomes data across the Caris Centers of Excellence for Precision Medicine Network.
The Pazdurs in their garden in Bethesda, with their dog, Cleo.The dog's full name is Cleopatra, Queen of Denial.The job interview wouldn't last more than 15 minutes, Richard Pazdur believed.
Roche and Upsher-Smith Laboratories Inc., through its wholly-owned U.K. subsidiary Proximagen Ltd., announced a worldwide agreement for the further development of a novel, oral small molecule inhibitor of Vascular Adhesion Protein 1, a cell-adhesion molecule that may be effective in the treatment of inflammatory disease. The VAP-1 inhibitor is currently in phase II clinical development.
The European Medicines Agency accepted a marketing authorization application for review of anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer patients. Anamorelin is being developed by Helsinn.
